. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2019 Jun 15;25(10):1984–1992. doi: 10.1016/j.bbmt.2019.06.007

Table 6.

Patient disposition

	Total (N=63)
Months of follow-up for survivors, median (95% CI)	58.9 mo (53.1–62.6)

Primary off treatment reason
Treatment completed per protocol	17 (27.0%)
Disease progression	10 (15.9%)
Adverse event	10 (15.9%)
Died during treatment	12 (19.0%)
Patient refused further protocol treatment	10 (14.9%)
Other¹	4 (6.4%)

^1:

Patient scheduled to receive bone marrow stem cells not allowed per protocol; could not start AZA due to low ANC on day 90; Pt started on Valcyte for CMV which caused low counts, never met criteria to start AZA; Treatment delayed greater than 4 weeks due to AE not related to protocol